Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present at H.C. Wainwright’s 23rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.
Cassava Sciences’ presentation is a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.
| Event details follow: | |
| Date: | Monday, September 13th |
| Time: | 7:00 a.m. Eastern Time |
| Webcast: | https://www.CassavaSciences.com/company-presentations |
Cassava Sciences’ fireside chat will be available for replay for 90 days following the conference on www.CassavaSciences.com in the ‘Investors’ section.
About Alzheimer’s Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to over 150 million by 2050.1 The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization.
About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease.
Simufilam and SavaDx were both developed in-house. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer’s disease, and related technologies, without royalty obligations to any third party.
For more information, please visit https://www.CassavaSciences.com
Contact Information:
Eric Schoen, Chief Financial Officer
Cassava Sciences, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
(512) 501-2450
1 Alzheimer's Disease International, Dementia Statistics, available on-line and accessed September 8, 2021.
| Last Trade: | US$2.59 |
| Daily Change: | -0.03 -1.15 |
| Daily Volume: | 1,221,331 |
| Market Cap: | US$124.600M |
November 25, 2024 November 07, 2024 September 24, 2024 September 09, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
